Literature DB >> 30715417

Correlations Between Human Immunodeficiency Virus (HIV) Infection and Rectal Gonorrhea Incidence in Men Who Have Sex With Men: Implications for Future HIV Preexposure Prophylaxis Trials.

Charu Mullick1, Jeffrey Murray1.   

Abstract

Using published data, we found a direct correlation between the incidence of rectal gonorrhea and human immunodeficiency virus (HIV) infection in men who have sex with men who were not using oral preexposure prophylaxis. HIV incidence was predicted using rectal gonorrhea incidence as the determinant in regression analysis. The observed correlation suggest that rectal gonorrhea incidence can potentially serve as a predictor of HIV incidence. If confirmed with additional data, a quantitative correlation for incidence of the 2 infections could be useful in active-controlled HIV prevention trials where low HIV incidence is expected. Widespread improvements in treatment as prevention and gonorrhea control can negatively impact the correlation and its utility. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  HIV prevention; clinical trial designs; gonorrhea; preexposure prophylaxis

Mesh:

Year:  2020        PMID: 30715417     DOI: 10.1093/infdis/jiz037

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Novel Approaches for Development of Human Immunodeficiency Virus Preexposure Prophylaxis Agents.

Authors:  Myron S Cohen; Deborah Donnell
Journal:  J Infect Dis       Date:  2020-01-02       Impact factor: 5.226

2.  Sample size calculation for active-arm trial with counterfactual incidence based on recency assay.

Authors:  Fei Gao; David V Glidden; James P Hughes; Deborah J Donnell
Journal:  Stat Commun Infect Dis       Date:  2021-11-10

Review 3.  A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial.

Authors:  David V Glidden; Oliver T Stirrup; David T Dunn
Journal:  Lancet HIV       Date:  2020-11       Impact factor: 12.767

4.  Advancing Novel PrEP Products - Alternatives to Non-Inferiority.

Authors:  David V Glidden
Journal:  Stat Commun Infect Dis       Date:  2019-08-06

Review 5.  Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis.

Authors:  David V Glidden
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061

6.  Risk of HIV Diagnosis Following Bacterial Sexually Transmitted Infections in Tennessee, 2013-2017.

Authors:  Heather N Grome; Peter F Rebeiro; Meredith Brantley; Dyanne Herrera-Vasquez; Samantha A Mathieson; April C Pettit
Journal:  Sex Transm Dis       Date:  2021-11-01       Impact factor: 3.868

7.  Optimizing Screening for HIV.

Authors:  Antoine Chaillon; Martin Hoenigl; Lorri Freitas; Haruna Feldman; Winston Tilghman; Lawrence Wang; Davey Smith; Susan Little; Sanjay R Mehta
Journal:  Open Forum Infect Dis       Date:  2020-01-19       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.